KPV Compounding Legality: Straight Answers to Common Questions

KPV keeps showing up in peptide clinics and online forums as a treatment idea for inflammatory bowel disease, eczema, psoriasis, and general "gut and skin inflammation." The clinical rationale traces back to lab and animal work on alpha-MSH-derived peptides, not to a body of human trials. The regulatory picture is just as unsettled, and unsettled is not the same as illegal or the same as legal. Below are the specific questions people ask, answered without softening the uncertainty.

Is KPV FDA approved?

No. KPV has no FDA-approved drug application for any indication, human or veterinary. There is no brand-name product, no approved label, no approved dose. Any use in patients today is either compounded, sold as a research chemical, or offered through some other unregulated channel, none of which carries FDA approval.

Is KPV legal to compound?

This is the question people actually want answered, and the honest response is: it depends on which legal test you apply, and right now KPV fails the clearest one.

Under section 503A of the FD&C Act, a compounding pharmacy can generally use a bulk drug substance only if that substance appears on the FDA's 503A bulks list, or the compounding otherwise fits within the statute's narrower allowances (for example, compounding from an FDA-approved drug). KPV is not on the 503A bulks list. That is the controlling fact. The FDA's framework page describing this list and its criteria is here: FDA's 503A bulk drug substances framework.

Separately, the FDA maintains a Category 2 list of bulk substances nominated for compounding that the agency has flagged as presenting significant safety risks, which triggers enforcement priority against compounders using them. KPV's nomination to that list was withdrawn by the nominators, and as of the FDA's Category 2 page (content current 04/22/2026) KPV no longer appears there: FDA Category 2 bulk drug substances page.

Withdrawal from Category 2 removes a specific enforcement flag. It does not add KPV to the 503A list, does not approve it, and does not create any interim enforcement discretion policy that would authorize compounding it. In plain terms: KPV is no longer on the "we're specifically watching this as high-risk" list, but it was never on the "you may compound this" list either. A pharmacy compounding KPV today is doing so outside the clearly authorized 503A pathway, regardless of how the Category 2 situation resolved.

What did the FDA's advisory committee actually do in July 2026?

On July 23 to 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met and voted 8 yes, 6 no, 1 abstain to recommend that KPV be added to the 503A bulks list. The meeting record is here: July 2026 PCAC meeting page.

A PCAC vote is advisory. The committee reviews nominations and makes recommendations to the FDA; it does not have authority to add substances to the list itself, and the FDA is not bound to follow its recommendation on any particular timeline. As of September 2026, KPV is not on the 503A bulks list. The vote signals that a meaningful bloc of the advisory committee saw enough evidence to support compounding access, but a 8-6-1 split also shows this was not a consensus decision, and six members were not convinced. Readers should treat "PCAC recommended" and "FDA authorized" as two different facts that are easy to conflate.

Can doctors prescribe KPV right now?

A physician can write a prescription for a compounded preparation, but the pharmacy filling it needs a lawful basis to compound the active ingredient. With KPV off the 503A list, a compounding pharmacy filling that prescription is not doing so under the standard 503A bulk-substance authorization. Some pharmacies compound anyway, relying on other arguments (custom orders under narrower state pharmacy law provisions, or treating KPV as a component of another allowed process). Whether any specific pharmacy's practice is defensible is a legal and regulatory question outside the scope of this page; patients considering compounded KPV should ask the prescribing clinic and dispensing pharmacy directly how they justify sourcing it, and should treat vague reassurance ("it's legal, don't worry") as a warning sign rather than an answer.

What changed in April 2026, specifically?

The FDA's Category 2 bulk drug substances page shows content current as of 04/22/2026, reflecting that KPV's nomination to Category 2 had been withdrawn by the nominators by that point. That is the only April 2026 change supported by the source material here. It is a narrowing of the regulatory picture (KPV is not flagged as a specific enforcement-priority safety risk), not a broadening of it (KPV still is not authorized for compounding). Treat any claim that "KPV became legal in April 2026" as a misreading of this withdrawal.

Why does the underlying evidence matter for how you weigh the regulatory gap?

The regulatory uncertainty around KPV would matter less if there were a large human evidence base showing clear efficacy and safety, the kind of situation where a substance is compounded ahead of formal listing because clinicians and regulators broadly agree the risk-benefit is favorable. That is not where KPV sits. The mechanistic case for KPV rests substantially on cell-culture and rodent studies: reduced cytokine signaling in intestinal and bronchial epithelial models (Gastroenterology, 2008; International journal of physiology, pathophysiology and pharmacology, 2012), anti-inflammatory activity in murine colitis models (Inflammatory bowel diseases, 2008), and antimicrobial and immune-modulating effects described broadly in review literature (Endocrine reviews, 2008; Annals of the rheumatic diseases, 2007). Human clinical trial data for KPV specifically remain limited. That gap in human evidence is a separate problem from the regulatory gap, but the two compound each other: a substance with thin human trial data and no 503A listing carries more uncertainty than either fact alone would suggest.

A three-question filter before considering compounded KPV

Use this in order. If you cannot answer "yes, with documentation" to a question, treat the next step as unresolved rather than assuming it's fine.

1. Is the substance currently on the FDA's 503A bulks list? As of September 2026, no. This alone means any compounding pharmacy is working outside the standard authorized pathway, regardless of what a clinic tells you.
2. Has the FDA (not just the advisory committee) issued a final decision following the July 2026 PCAC recommendation? As of this writing, no final action has occurred. A "yes" here would require checking the current 503A list directly, since this status can change without much public notice.
3. Is the clinical indication being proposed backed by human trial evidence, or only cell-culture and animal-model evidence? For KPV, the human trial base is limited across the indications commonly discussed, including inflammatory bowel disease and skin inflammation. Cell and animal data support biological plausibility, not proven human efficacy.

If the answer to all three is "no" or "unresolved," the honest framing is: this is an unapproved, unlisted substance with limited human evidence, being offered off-label and outside a clear compounding authorization. That does not make it unsafe or worthless, but it does mean the burden of explanation sits with whoever is selling or prescribing it, not with the patient asking questions.

What this page does not resolve

This page addresses only the regulatory questions above. It does not evaluate specific formulations, does not provide dosing guidance, and does not substitute for a conversation with a prescribing clinician about individual risk, alternatives such as topical steroids, or how systemic KPV use is being positioned by any particular provider. For background on KPV's proposed mechanisms and the broader evidence landscape, see the KPV pillar page. If you develop worsening symptoms of the underlying condition you are treating, or experience an unexpected reaction to any compounded product, seek medical evaluation rather than waiting to see if it resolves.